Immunovant reports FY2023 net loss $211M; IMVT-1402 IND cleared, Phase 1 started

Immunovant, Inc.

2023-FY EPS reported -$1.71

Net loss of $59.4M ($0.46/share) for Q4 FY2023 vs $47.2M ($0.41) a year ago.
Full-year net loss $211.0M ($1.71/share) vs $156.7M ($1.43); cash $376.5M funding into H2 2025.
R&D expenses rose 61% YoY to $160.3M, driven by batoclimab and IMVT-1402 programs.
FDA IND and MEDSAFE CTA cleared for IMVT-1402; Phase 1 trial enrolling in New Zealand.
Initial Phase 1 data from single-ascending dose expected Aug/Sep 2023; MAD data Oct/Nov 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunovant, Inc. reported the three months ended March 31, 2023 results: net income $59.4 million, EPS $0.46 per common share.

Period: the three months ended March 31, 2023
Net income: $59.4 million
EPS: $0.46 per common share
Result: reported results

Exact text from the filing

Net loss was $59.4 million ($0.46 per common share) for the three months ended March 31, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunovant, Inc. reported the fiscal year ended March 31, 2023 results: net income $211.0 million, EPS $1.71 per common share.

Period: the fiscal year ended March 31, 2023
Net income: $211.0 million
EPS: $1.71 per common share
Result: reported results

Exact text from the filing

Net loss was $211.0 million ($1.71 per common share) for the fiscal year ended March 31, 2023

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.